Cancer procoagulant
 | This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. (March 2022) |
| Cancer procoagulant | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| EC no. | 3.4.22.26 | ||||||||
| CAS no. | 109456-80-6 | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
| |||||||||
Cancer procoagulant is a hypothesised protein, most likely a cysteine protease enzyme (EC 3.4.22.26), that occurs only in fetal and malignant cells. Its activity appears to be the activation of factor X, one of the coagulation factors, and would account for the increased incidence of thrombosis in cancer patients. Tissue factor (TF) is also known to be present at increased levels around malignant cells.
References
[edit]- De Cicco M (June 2004). "The prothrombotic state in cancer: pathogenic mechanisms". Critical Reviews in Oncology/Hematology. 50 (3): 187–96. doi:10.1016/j.critrevonc.2003.10.003. PMID 15182825.
External links
[edit]- cancer+procoagulant at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
 | This enzyme-related article is a stub. You can help Wikipedia by expanding it. |